Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 50

1.

An antibody tag-team: driving neutralization through escape.

Alter G, Ackerman ME.

Trends Immunol. 2014 Sep;35(9):403-5. doi: 10.1016/j.it.2014.07.009. Epub 2014 Aug 15.

PMID:
25131302
2.

Multiplexed screening of natural humoral immunity identifies antibodies at fine specificity for complex and dynamic viral targets.

McCutcheon KM, Gray J, Chen NY, Liu K, Park M, Ellsworth S, Tripp RA, Tompkins SM, Johnson SK, Samet S, Pereira L, Kauvar LM.

MAbs. 2014 Mar-Apr;6(2):460-73. doi: 10.4161/mabs.27760. Epub 2014 Jan 8.

3.

Clonal dominance: cause for a limited and failing immune response to HIV-1 infection and vaccination.

Kohler H, Goudsmit J, Nara P.

J Acquir Immune Defic Syndr. 1992;5(11):1158-68. Review.

PMID:
1403647
4.

Longitudinal Antigenic Sequences and Sites from Intra-Host Evolution (LASSIE) Identifies Immune-Selected HIV Variants.

Hraber P, Korber B, Wagh K, Giorgi EE, Bhattacharya T, Gnanakaran S, Lapedes AS, Learn GH, Kreider EF, Li Y, Shaw GM, Hahn BH, Montefiori DC, Alam SM, Bonsignori M, Moody MA, Liao HX, Gao F, Haynes BF.

Viruses. 2015 Oct 21;7(10):5443-75. doi: 10.3390/v7102881.

5.

B-cell responses to HIV infection.

Moir S, Fauci AS.

Immunol Rev. 2017 Jan;275(1):33-48. doi: 10.1111/imr.12502. Review.

6.

Chikungunya virus neutralization antigens and direct cell-to-cell transmission are revealed by human antibody-escape mutants.

Lee CY, Kam YW, Fric J, Malleret B, Koh EG, Prakash C, Huang W, Lee WW, Lin C, Lin RT, Renia L, Wang CI, Ng LF, Warter L.

PLoS Pathog. 2011 Dec;7(12):e1002390. doi: 10.1371/journal.ppat.1002390. Epub 2011 Dec 1.

7.

GP4-specific neutralizing antibodies might be a driving force in PRRSV evolution.

Costers S, Vanhee M, Van Breedam W, Van Doorsselaere J, Geldhof M, Nauwynck HJ.

Virus Res. 2010 Dec;154(1-2):104-13. doi: 10.1016/j.virusres.2010.08.026. Epub 2010 Sep 15. Review.

PMID:
20837070
8.

A cell-to-cell HIV transfer assay identifies humoral responses with broad neutralization activity.

Sánchez-Palomino S, Massanella M, Carrillo J, García A, García F, González N, Merino A, Alcamí J, Bofill M, Yuste E, Gatell JM, Clotet B, Blanco J.

Vaccine. 2011 Jul 18;29(32):5250-9. doi: 10.1016/j.vaccine.2011.05.016. Epub 2011 May 24.

PMID:
21609746
9.

On the benefits of sin: can greater understanding of the 1F7-idiotypic repertoire freeze enhance HIV vaccine development?

Parsons MS, Muller S, Kohler H, Grant MD, Bernard NF.

Hum Vaccin Immunother. 2013 Jul;9(7):1532-8. doi: 10.4161/hv.24460. Epub 2013 Apr 9. Review.

PMID:
23571168
10.

Cytotoxic T cell and neutralizing antibody responses to human immunodeficiency virus type 1 envelope with a combination vaccine regimen. AIDS Vaccine Evaluation Group.

Corey L, McElrath MJ, Weinhold K, Matthews T, Stablein D, Graham B, Keefer M, Schwartz D, Gorse G.

J Infect Dis. 1998 Feb;177(2):301-9.

PMID:
9466515
11.

The role of recombination for the coevolutionary dynamics of HIV and the immune response.

Mostowy R, Kouyos RD, Fouchet D, Bonhoeffer S.

PLoS One. 2011 Feb 18;6(2):e16052. doi: 10.1371/journal.pone.0016052.

12.

Polyvalent human immunodeficiency virus synthetic immunogen comprised of envelope gp120 T helper cell sites and B cell neutralization epitopes.

Palker TJ, Matthews TJ, Langlois A, Tanner ME, Martin ME, Scearce RM, Kim JE, Berzofsky JA, Bolognesi DP, Haynes BF.

J Immunol. 1989 May 15;142(10):3612-9.

PMID:
2469721
13.

Loss of HIV-specific memory B-cells as a potential mechanism for the dysfunction of the humoral immune response against HIV.

Bussmann BM, Reiche S, Bieniek B, Krznaric I, Ackermann F, Jassoy C.

Virology. 2010 Feb 5;397(1):7-13. doi: 10.1016/j.virol.2009.11.003. Epub 2009 Dec 4.

14.

Is autoimmunity a component of natural immunity to HIV?

Russo S, Lopalco L.

Curr HIV Res. 2006 Apr;4(2):177-90. Review.

PMID:
16611056
15.

A synthetic peptide encompassing the G5 antigenic region of the rabies virus induces high avidity but poorly neutralizing antibody in immunized animals.

Niederhäuser S, Bruegger D, Zahno ML, Vogt HR, Peterhans E, Zanoni R, Bertoni G.

Vaccine. 2008 Dec 9;26(52):6749-53. doi: 10.1016/j.vaccine.2008.10.020. Epub 2008 Oct 26.

PMID:
18955098
16.

Neutralizing antibodies and pathogenesis of hepatitis C virus infection.

Fafi-Kremer S, Fauvelle C, Felmlee DJ, Zeisel MB, Lepiller Q, Fofana I, Heydmann L, Stoll-Keller F, Baumert TF.

Viruses. 2012 Oct 9;4(10):2016-30. doi: 10.3390/v4102016. Review.

17.

Mechanisms of hypergammaglobulinemia and impaired antigen-specific humoral immunity in HIV-1 infection.

De Milito A, Nilsson A, Titanji K, Thorstensson R, Reizenstein E, Narita M, Grutzmeier S, Sönnerborg A, Chiodi F.

Blood. 2004 Mar 15;103(6):2180-6. Epub 2003 Nov 6.

18.

Aiming to induce broadly reactive neutralizing antibody responses with HIV-1 vaccine candidates.

Haynes BF, Montefiori DC.

Expert Rev Vaccines. 2006 Aug;5(4):579-95. Review.

PMID:
16989638
19.

Virus-specific antibody production and polyclonal B-cell activation in the intestinal mucosa of HIV-infected individuals.

Eriksson K, Kilander A, Hagberg L, Norkrans G, Holmgren J, Czerkinsky C.

AIDS. 1995 Jul;9(7):695-700.

PMID:
7546413
20.

Potent high-affinity antibodies for treatment and prophylaxis of respiratory syncytial virus derived from B cells of infected patients.

Collarini EJ, Lee FE, Foord O, Park M, Sperinde G, Wu H, Harriman WD, Carroll SF, Ellsworth SL, Anderson LJ, Tripp RA, Walsh EE, Keyt BA, Kauvar LM.

J Immunol. 2009 Nov 15;183(10):6338-45. doi: 10.4049/jimmunol.0901373. Epub 2009 Oct 19.

Supplemental Content

Support Center